Immunotherapy for newly diagnosed high-grade brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (relatlimab and nivolumab) for newly diagnosed high-grade gliomas and brainstem tumors that have specific genetic mutations. The goal is to see if this treatment approach can help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12–39 years old and weigh at least 40 kg (or 30 kg outside the US)
- Newly diagnosed high-grade glioma (Grade 3 or 4) confirmed by biopsy, including DIPG (brainstem tumors)
- Your tumor must show DNA repair gene mutations—detected by blood tests, tumor testing, or genetic analysis
- Completed standard radiation therapy (54 Gy for most cases) within the past 8 weeks
- Good overall health with normal blood counts, kidney, and heart function
- No active infections, heart disease, autoimmune disease, HIV, or hepatitis B; not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
This trial tests a drug called tovorafenib for children and young adults with high-grade glioma or DIPG that has a specific change in the MAPK pathway. It looks at whether this targeted therapy can help after radiation treatment.
This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.